ParkinsonFranceV1, Main, Curation, bibRecord, 005002

Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study

Identifieur interne : 005002 ( Main/Curation ); précédent : 005001; suivant : 005003

Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study

Auteurs : H. Allain ; F. Le Coz ; F. Goulley ; F. Brunet-Bourgin ; Y. Loria ; D. Bentue-Ferrer ; R. Decombe ; J.-M. Reymann ; P. Chaumet-Riffaud ; J.-M. Gandon

Source :

International journal of clinical pharmacology, therapy and toxicology : (1980) [ 0174-4879 ] ; 1991.

RBID : Pascal:91-0549078

Descripteurs français

Pascal (Inist)
- Antiparkinsonien, Stimulant dopaminergique, Association médicamenteuse, Forme pharmaceutique, Traitement, Chimiothérapie, Homme, Système nerveux pathologie, Récepteur dopaminergique D2, Forme libération contrôlée, Parkinson maladie, Essai thérapeutique contrôlé, Dopa, Bromocriptine, Essai clinique.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Adult, Aged, Aged, 80 and over, Antiparkinson agent, Behavior (drug effects), Bromocriptine (administration & dosage), Bromocriptine (adverse effects), Bromocriptine (therapeutic use), Bromocryptine, Chemotherapy, Clinical trial, Controlled release form, Controlled therapeutic trial, D2 Dopamine receptor, Delayed-Action Preparations, Dopa, Dopamine agonist, Dosage form, Double-Blind Method, Drug combination, Female, Human, Humans, Levodopa (therapeutic use), Male, Middle Aged, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson Disease (psychology), Parkinson disease, Treatment.
MESH :
- chemical , administration & dosage : Bromocriptine.
- chemical , adverse effects : Bromocriptine.
- drug effects : Behavior.
- drug therapy : Parkinson Disease.
- metabolism : Parkinson Disease.
- psychology : Parkinson Disease.
- chemical , therapeutic use : Bromocriptine, Levodopa.
- Adult, Aged, Aged, 80 and over, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Male, Middle Aged.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001B73
to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :001478
to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001A16
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :005A66
to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001788
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001747
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001747
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000720
to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000720
to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000720
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :005913

Links to Exploration step

Pascal:91-0549078

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study</title>
<author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name>
</author>
<author><name sortKey="Le Coz, F" sort="Le Coz, F" uniqKey="Le Coz F" first="F." last="Le Coz">F. Le Coz</name>
</author>
<author><name sortKey="Goulley, F" sort="Goulley, F" uniqKey="Goulley F" first="F." last="Goulley">F. Goulley</name>
</author>
<author><name sortKey="Brunet Bourgin, F" sort="Brunet Bourgin, F" uniqKey="Brunet Bourgin F" first="F." last="Brunet-Bourgin">F. Brunet-Bourgin</name>
</author>
<author><name sortKey="Loria, Y" sort="Loria, Y" uniqKey="Loria Y" first="Y." last="Loria">Y. Loria</name>
</author>
<author><name sortKey="Bentue Ferrer, D" sort="Bentue Ferrer, D" uniqKey="Bentue Ferrer D" first="D." last="Bentue-Ferrer">D. Bentue-Ferrer</name>
</author>
<author><name sortKey="Decombe, R" sort="Decombe, R" uniqKey="Decombe R" first="R." last="Decombe">R. Decombe</name>
</author>
<author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J.-M." last="Reymann">J.-M. Reymann</name>
</author>
<author><name sortKey="Chaumet Riffaud, P" sort="Chaumet Riffaud, P" uniqKey="Chaumet Riffaud P" first="P." last="Chaumet-Riffaud">P. Chaumet-Riffaud</name>
</author>
<author><name sortKey="Gandon, J M" sort="Gandon, J M" uniqKey="Gandon J" first="J.-M." last="Gandon">J.-M. Gandon</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">91-0549078</idno>
<date when="1991">1991</date>
<idno type="stanalyst">PASCAL 91-0549078 INIST</idno>
<idno type="RBID">Pascal:91-0549078</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001B73</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001478</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001A16</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001A16</idno>
<idno type="wicri:doubleKey">0174-4879:1991:Allain H:comparison:of:three</idno>
<idno type="wicri:Area/Main/Merge">005A66</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:1743806</idno>
<idno type="wicri:Area/PubMed/Corpus">001788</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001788</idno>
<idno type="wicri:Area/PubMed/Curation">001747</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001747</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001747</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001747</idno>
<idno type="wicri:Area/Ncbi/Merge">000720</idno>
<idno type="wicri:Area/Ncbi/Curation">000720</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000720</idno>
<idno type="wicri:doubleKey">0174-4879:1991:Allain H:comparison:of:three</idno>
<idno type="wicri:Area/Main/Merge">005913</idno>
<idno type="wicri:Area/Main/Curation">005002</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study</title>
<author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name>
</author>
<author><name sortKey="Le Coz, F" sort="Le Coz, F" uniqKey="Le Coz F" first="F." last="Le Coz">F. Le Coz</name>
</author>
<author><name sortKey="Goulley, F" sort="Goulley, F" uniqKey="Goulley F" first="F." last="Goulley">F. Goulley</name>
</author>
<author><name sortKey="Brunet Bourgin, F" sort="Brunet Bourgin, F" uniqKey="Brunet Bourgin F" first="F." last="Brunet-Bourgin">F. Brunet-Bourgin</name>
</author>
<author><name sortKey="Loria, Y" sort="Loria, Y" uniqKey="Loria Y" first="Y." last="Loria">Y. Loria</name>
</author>
<author><name sortKey="Bentue Ferrer, D" sort="Bentue Ferrer, D" uniqKey="Bentue Ferrer D" first="D." last="Bentue-Ferrer">D. Bentue-Ferrer</name>
</author>
<author><name sortKey="Decombe, R" sort="Decombe, R" uniqKey="Decombe R" first="R." last="Decombe">R. Decombe</name>
</author>
<author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J.-M." last="Reymann">J.-M. Reymann</name>
</author>
<author><name sortKey="Chaumet Riffaud, P" sort="Chaumet Riffaud, P" uniqKey="Chaumet Riffaud P" first="P." last="Chaumet-Riffaud">P. Chaumet-Riffaud</name>
</author>
<author><name sortKey="Gandon, J M" sort="Gandon, J M" uniqKey="Gandon J" first="J.-M." last="Gandon">J.-M. Gandon</name>
</author>
</analytic>
<series><title level="j" type="main">International journal of clinical pharmacology, therapy and toxicology : (1980)</title>
<title level="j" type="abbreviated">Int. j. clin. pharmacol. ther. toxicol. : (1980)</title>
<idno type="ISSN">0174-4879</idno>
<imprint><date when="1991">1991</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">International journal of clinical pharmacology, therapy and toxicology : (1980)</title>
<title level="j" type="abbreviated">Int. j. clin. pharmacol. ther. toxicol. : (1980)</title>
<idno type="ISSN">0174-4879</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antiparkinson agent</term>
<term>Behavior (drug effects)</term>
<term>Bromocriptine (administration & dosage)</term>
<term>Bromocriptine (adverse effects)</term>
<term>Bromocriptine (therapeutic use)</term>
<term>Bromocryptine</term>
<term>Chemotherapy</term>
<term>Clinical trial</term>
<term>Controlled release form</term>
<term>Controlled therapeutic trial</term>
<term>D2 Dopamine receptor</term>
<term>Delayed-Action Preparations</term>
<term>Dopa</term>
<term>Dopamine agonist</term>
<term>Dosage form</term>
<term>Double-Blind Method</term>
<term>Drug combination</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bromocriptine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bromocriptine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bromocriptine</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Delayed-Action Preparations</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term>
<term>Stimulant dopaminergique</term>
<term>Association médicamenteuse</term>
<term>Forme pharmaceutique</term>
<term>Traitement</term>
<term>Chimiothérapie</term>
<term>Homme</term>
<term>Système nerveux pathologie</term>
<term>Récepteur dopaminergique D2</term>
<term>Forme libération contrôlée</term>
<term>Parkinson maladie</term>
<term>Essai thérapeutique contrôlé</term>
<term>Dopa</term>
<term>Bromocriptine</term>
<term>Essai clinique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<double idat="0174-4879:1991:Allain H:comparison:of:three"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study</title>
<author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name>
</author>
<author><name sortKey="Le Coz, F" sort="Le Coz, F" uniqKey="Le Coz F" first="F." last="Le Coz">F. Le Coz</name>
</author>
<author><name sortKey="Goulley, F" sort="Goulley, F" uniqKey="Goulley F" first="F." last="Goulley">F. Goulley</name>
</author>
<author><name sortKey="Brunet Bourgin, F" sort="Brunet Bourgin, F" uniqKey="Brunet Bourgin F" first="F." last="Brunet-Bourgin">F. Brunet-Bourgin</name>
</author>
<author><name sortKey="Loria, Y" sort="Loria, Y" uniqKey="Loria Y" first="Y." last="Loria">Y. Loria</name>
</author>
<author><name sortKey="Bentue Ferrer, D" sort="Bentue Ferrer, D" uniqKey="Bentue Ferrer D" first="D." last="Bentue-Ferrer">D. Bentue-Ferrer</name>
</author>
<author><name sortKey="Decombe, R" sort="Decombe, R" uniqKey="Decombe R" first="R." last="Decombe">R. Decombe</name>
</author>
<author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J.-M." last="Reymann">J.-M. Reymann</name>
</author>
<author><name sortKey="Chaumet Riffaud, P" sort="Chaumet Riffaud, P" uniqKey="Chaumet Riffaud P" first="P." last="Chaumet-Riffaud">P. Chaumet-Riffaud</name>
</author>
<author><name sortKey="Gandon, J M" sort="Gandon, J M" uniqKey="Gandon J" first="J.-M." last="Gandon">J.-M. Gandon</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">91-0549078</idno>
<date when="1991">1991</date>
<idno type="stanalyst">PASCAL 91-0549078 INIST</idno>
<idno type="RBID">Pascal:91-0549078</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001B73</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001478</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001A16</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001A16</idno>
<idno type="wicri:doubleKey">0174-4879:1991:Allain H:comparison:of:three</idno>
<idno type="wicri:Area/Main/Merge">005A66</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study</title>
<author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name>
</author>
<author><name sortKey="Le Coz, F" sort="Le Coz, F" uniqKey="Le Coz F" first="F." last="Le Coz">F. Le Coz</name>
</author>
<author><name sortKey="Goulley, F" sort="Goulley, F" uniqKey="Goulley F" first="F." last="Goulley">F. Goulley</name>
</author>
<author><name sortKey="Brunet Bourgin, F" sort="Brunet Bourgin, F" uniqKey="Brunet Bourgin F" first="F." last="Brunet-Bourgin">F. Brunet-Bourgin</name>
</author>
<author><name sortKey="Loria, Y" sort="Loria, Y" uniqKey="Loria Y" first="Y." last="Loria">Y. Loria</name>
</author>
<author><name sortKey="Bentue Ferrer, D" sort="Bentue Ferrer, D" uniqKey="Bentue Ferrer D" first="D." last="Bentue-Ferrer">D. Bentue-Ferrer</name>
</author>
<author><name sortKey="Decombe, R" sort="Decombe, R" uniqKey="Decombe R" first="R." last="Decombe">R. Decombe</name>
</author>
<author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J.-M." last="Reymann">J.-M. Reymann</name>
</author>
<author><name sortKey="Chaumet Riffaud, P" sort="Chaumet Riffaud, P" uniqKey="Chaumet Riffaud P" first="P." last="Chaumet-Riffaud">P. Chaumet-Riffaud</name>
</author>
<author><name sortKey="Gandon, J M" sort="Gandon, J M" uniqKey="Gandon J" first="J.-M." last="Gandon">J.-M. Gandon</name>
</author>
</analytic>
<series><title level="j" type="main">International journal of clinical pharmacology, therapy and toxicology : (1980)</title>
<title level="j" type="abbreviated">Int. j. clin. pharmacol. ther. toxicol. : (1980)</title>
<idno type="ISSN">0174-4879</idno>
<imprint><date when="1991">1991</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">International journal of clinical pharmacology, therapy and toxicology : (1980)</title>
<title level="j" type="abbreviated">Int. j. clin. pharmacol. ther. toxicol. : (1980)</title>
<idno type="ISSN">0174-4879</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Bromocryptine</term>
<term>Chemotherapy</term>
<term>Clinical trial</term>
<term>Controlled release form</term>
<term>Controlled therapeutic trial</term>
<term>D2 Dopamine receptor</term>
<term>Dopa</term>
<term>Dopamine agonist</term>
<term>Dosage form</term>
<term>Drug combination</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term>
<term>Stimulant dopaminergique</term>
<term>Association médicamenteuse</term>
<term>Forme pharmaceutique</term>
<term>Traitement</term>
<term>Chimiothérapie</term>
<term>Homme</term>
<term>Système nerveux pathologie</term>
<term>Récepteur dopaminergique D2</term>
<term>Forme libération contrôlée</term>
<term>Parkinson maladie</term>
<term>Essai thérapeutique contrôlé</term>
<term>Dopa</term>
<term>Bromocriptine</term>
<term>Essai clinique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
</INIST>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians: a randomized double-blind crossover study.</title>
<author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H" last="Allain">H. Allain</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Neurology and Neuropharmacology, University Hospital, Rennes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Neurology and Neuropharmacology, University Hospital, Rennes</wicri:regionArea>
<placeName><region type="region">Région Bretagne</region>
<region type="old region">Région Bretagne</region>
<settlement type="city">Rennes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Le Coz, F" sort="Le Coz, F" uniqKey="Le Coz F" first="F" last="Le Coz">F. Le Coz</name>
</author>
<author><name sortKey="Goulley, F" sort="Goulley, F" uniqKey="Goulley F" first="F" last="Goulley">F. Goulley</name>
</author>
<author><name sortKey="Brunet Bourgin, F" sort="Brunet Bourgin, F" uniqKey="Brunet Bourgin F" first="F" last="Brunet-Bourgin">F. Brunet-Bourgin</name>
</author>
<author><name sortKey="Loria, Y" sort="Loria, Y" uniqKey="Loria Y" first="Y" last="Loria">Y. Loria</name>
</author>
<author><name sortKey="Bentue Ferrer, D" sort="Bentue Ferrer, D" uniqKey="Bentue Ferrer D" first="D" last="Bentue-Ferrer">D. Bentue-Ferrer</name>
</author>
<author><name sortKey="Decombe, R" sort="Decombe, R" uniqKey="Decombe R" first="R" last="Decombe">R. Decombe</name>
</author>
<author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J M" last="Reymann">J M Reymann</name>
</author>
<author><name sortKey="Chaumet Riffaud, P" sort="Chaumet Riffaud, P" uniqKey="Chaumet Riffaud P" first="P" last="Chaumet-Riffaud">P. Chaumet-Riffaud</name>
</author>
<author><name sortKey="Gandon, J M" sort="Gandon, J M" uniqKey="Gandon J" first="J M" last="Gandon">J M Gandon</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1991">1991</date>
<idno type="RBID">pubmed:1743806</idno>
<idno type="pmid">1743806</idno>
<idno type="wicri:Area/PubMed/Corpus">001788</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001788</idno>
<idno type="wicri:Area/PubMed/Curation">001747</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001747</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001747</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001747</idno>
<idno type="wicri:Area/Ncbi/Merge">000720</idno>
<idno type="wicri:Area/Ncbi/Curation">000720</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000720</idno>
<idno type="wicri:doubleKey">0174-4879:1991:Allain H:comparison:of:three</idno>
<idno type="wicri:Area/Main/Merge">005913</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians: a randomized double-blind crossover study.</title>
<author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H" last="Allain">H. Allain</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Neurology and Neuropharmacology, University Hospital, Rennes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Neurology and Neuropharmacology, University Hospital, Rennes</wicri:regionArea>
<placeName><region type="region">Région Bretagne</region>
<region type="old region">Région Bretagne</region>
<settlement type="city">Rennes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Le Coz, F" sort="Le Coz, F" uniqKey="Le Coz F" first="F" last="Le Coz">F. Le Coz</name>
</author>
<author><name sortKey="Goulley, F" sort="Goulley, F" uniqKey="Goulley F" first="F" last="Goulley">F. Goulley</name>
</author>
<author><name sortKey="Brunet Bourgin, F" sort="Brunet Bourgin, F" uniqKey="Brunet Bourgin F" first="F" last="Brunet-Bourgin">F. Brunet-Bourgin</name>
</author>
<author><name sortKey="Loria, Y" sort="Loria, Y" uniqKey="Loria Y" first="Y" last="Loria">Y. Loria</name>
</author>
<author><name sortKey="Bentue Ferrer, D" sort="Bentue Ferrer, D" uniqKey="Bentue Ferrer D" first="D" last="Bentue-Ferrer">D. Bentue-Ferrer</name>
</author>
<author><name sortKey="Decombe, R" sort="Decombe, R" uniqKey="Decombe R" first="R" last="Decombe">R. Decombe</name>
</author>
<author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J M" last="Reymann">J M Reymann</name>
</author>
<author><name sortKey="Chaumet Riffaud, P" sort="Chaumet Riffaud, P" uniqKey="Chaumet Riffaud P" first="P" last="Chaumet-Riffaud">P. Chaumet-Riffaud</name>
</author>
<author><name sortKey="Gandon, J M" sort="Gandon, J M" uniqKey="Gandon J" first="J M" last="Gandon">J M Gandon</name>
</author>
</analytic>
<series><title level="j">International journal of clinical pharmacology, therapy, and toxicology</title>
<idno type="ISSN">0174-4879</idno>
<imprint><date when="1991" type="published">1991</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Behavior (drug effects)</term>
<term>Bromocriptine (administration & dosage)</term>
<term>Bromocriptine (adverse effects)</term>
<term>Bromocriptine (therapeutic use)</term>
<term>Delayed-Action Preparations</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (psychology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bromocriptine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bromocriptine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bromocriptine</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Delayed-Action Preparations</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Parlodel-SRO is a newly developed slow-release formulation of bromocriptine, which prevents initial plasma peak--a known source of adverse events--and extends the half-life of the compound, an interesting feature for the management of motor symptoms in Parkinsonians. This study was designed to determine the best daily administration schedule for 30 mg Parlodel-SRO in 18 parkinsonians previously treated with levodopa and standard Bromocriptine (Br). The 30 mg dose was replaced from one day to the next, in a randomized, double-blind latin square design trial. Three consecutive 7-day courses were implemented, during which a total daily dose of 30 mg P-SRO was administered in one dose, two intakes (b.i.d.) and three intakes, (t.i.d.) respectively. The b.i.d. schedule produced the best improvement in UPDRS scores, especially as to postural stability, walking, bradykinesia; it also provided greater pharmacological stability throughout the assessment day. Adverse event analysis was not in favor of a single daily dose. It appeared that P-SRO administered in two 15 mg intakes (morning and evening) produces the best benefit-risk ratio in Parkinsonians who were already being treated with levodopa.</div>
</front>
</TEI>
</PubMed>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005002 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 005002 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:91-0549078
   |texte=   Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study

Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri